Published in

Oxford University Press, Open Forum Infectious Diseases, 7(9), 2022

DOI: 10.1093/ofid/ofac283

Links

Tools

Export citation

Search in Google Scholar

Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis

Journal article published in 2022 by Eloy E. Ordaya ORCID, Elena Beam ORCID, Joseph D. Yao ORCID, Raymund R. Razonable, Paschalis Vergidis ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
White circle
Published version: policy unclear
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Abstract Tixagevimab-cilgavimab is authorized for preexposure prophylaxis against coronavirus disease 2019 (COVID-19) in immunocompromised hosts. Herein, we report the clinical characteristics of 8 patients who developed COVID-19 soon after receiving tixagevimab-cilgavimab. This study emphasizes the need to maintain additional measures to prevent COVID-19 during periods of high severe acute respiratory syndrome coronavirus 2 transmission.